Insights into the genetic regulatory landscape of GB have been achieved through The Cancer Genome Atlas28 and identified abnormalities of several causal genes, including Idh1, Egfr.29 Furthermore, patterns of gene expression have been collated to identify molecular subgroups with putative prognostic or predictive significance.30 Here, we identified that CLEC5A is a critical protein linked with GBM pathology and clinical outcome. This evidence concerns the gene CLEC5A and glioblastoma.